34 related articles for article (PubMed ID: 18586384)
1. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Cumashi A; Tinari N; Rossi C; Lattanzio R; Natoli C; Piantelli M; Iacobelli S
Cancer Lett; 2008 Nov; 270(2):229-33. PubMed ID: 18586384
[TBL] [Abstract][Full Text] [Related]
2. A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro.
Chen Y; Wang H; Zuo Y; Li N; Ding M; Li C
Cancer Med; 2018 May; 7(5):2064-2077. PubMed ID: 29577645
[TBL] [Abstract][Full Text] [Related]
3. The role of LASS2 in regulating bladder cancer cell tumorigenicity in a nude mouse model.
Chen Y; Wang H; Xiong T; Zou R; Tang Z; Wang J
Oncol Lett; 2017 Nov; 14(5):5149-5156. PubMed ID: 29113153
[TBL] [Abstract][Full Text] [Related]
4. Effects of Shugan Jianpi Formula () on myeloid-derived suppression cells-mediated depression breast cancer mice.
Lu YT; Li J; Qi X; Pei YX; Shi WG; Lin HS
Chin J Integr Med; 2017 Jun; 23(6):453-460. PubMed ID: 27796822
[TBL] [Abstract][Full Text] [Related]
5. Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis.
Nguyen L; Fifis T; Christophi C
BMC Cancer; 2016 Jul; 16():533. PubMed ID: 27460820
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model.
Kumar RM; Arlt MJ; Kuzmanov A; Born W; Fuchs B
Am J Cancer Res; 2015; 5(7):2156-68. PubMed ID: 26328246
[TBL] [Abstract][Full Text] [Related]
7. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis.
Yin T; He S; Ye T; Shen G; Wan Y; Wang Y
Transl Oncol; 2014 Apr; 7(2):221-9. PubMed ID: 24742865
[TBL] [Abstract][Full Text] [Related]
9. Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Wang L; Huang X; Zheng X; Wang X; Li S; Zhang L; Yang Z
Clin Transl Oncol; 2014 Jun; 16(6):567-72. PubMed ID: 24105048
[TBL] [Abstract][Full Text] [Related]
10. Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Ketola K; Kallioniemi O; Iljin K
PLoS One; 2012; 7(12):e51470. PubMed ID: 23251544
[TBL] [Abstract][Full Text] [Related]
11. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
Jing C; Ning J; Yuanjie N
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2137-43. PubMed ID: 22868821
[TBL] [Abstract][Full Text] [Related]
12. Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Altavilla A; Iacovelli R; Procopio G; Alesini D; Risi E; Campennì GM; Palazzo A; Cortesi E
Cancer Biol Ther; 2012 Sep; 13(11):1001-8. PubMed ID: 22825325
[TBL] [Abstract][Full Text] [Related]
13. Progress of molecular targeted therapies for prostate cancers.
Fu W; Madan E; Yee M; Zhang H
Biochim Biophys Acta; 2012 Apr; 1825(2):140-52. PubMed ID: 22146293
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Kutikov A; Makhov P; Golovine K; Canter DJ; Sirohi M; Street R; Simhan J; Uzzo RG; Kolenko VM
Urology; 2011 Oct; 78(4):968.e7-11. PubMed ID: 21982018
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of human Ewing/PNET sarcoma models.
Teicher BA; Bagley RG; Rouleau C; Kruger A; Ren Y; Kurtzberg L
Ann Saudi Med; 2011; 31(2):174-82. PubMed ID: 21422656
[TBL] [Abstract][Full Text] [Related]
17. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Tran Cao HS; Bouvet M; Kaushal S; Keleman A; Romney E; Kim G; Fruehauf J; Imagawa DK; Hoffman RM; Katz MH
Mol Cancer Ther; 2010 Jul; 9(7):2068-78. PubMed ID: 20606044
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.
Hui EP; Lui VW; Wong CS; Ma BB; Lau CP; Cheung CS; Ho K; Cheng SH; Ng MH; Chan AT
Invest New Drugs; 2011 Dec; 29(6):1123-31. PubMed ID: 20467883
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment.
Song IC; Lim JS; Yun HJ; Kim S; Kang DY; Lee HJ
Jpn J Clin Oncol; 2009 Dec; 39(12):833-6. PubMed ID: 19773269
[TBL] [Abstract][Full Text] [Related]
20. RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.
Gust KM; Hofer MD; Perner SR; Kim R; Chinnaiyan AM; Varambally S; Moller P; Rinnab L; Rubin MA; Greiner J; Schmitt M; Kuefer R; Ringhoffer M
Neoplasia; 2009 Sep; 11(9):956-63. PubMed ID: 19724689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
